CVS director Mike Mahoney, whose day job is CEO of Boston Scientific, bought 30,000 shares of the healthcare company.

After underperforming throughout 2024, shares of CVS Health (NYSE: CVS) are surging. CVS Health stock is way up but still ...

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

CVS Health's adjusted EPS outlook for 2025 reflects expectations of a meaningful recovery in Medicare Advantage and continued ...

CVS Health (NYSE:CVS – Free Report) had its price target lifted by JPMorgan Chase & Co. from $80.00 to $81.00 in a report ...

Principal Securities Inc. grew its holdings in shares of CVS Health Co. (NYSE:CVS – Free Report) by 3.2% during the fourth ...

We recently compiled a list of the 10 Best Performing S&P 500 Stocks So Far in 2025. In this article, we are going to take a ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

CVS Health (CVS) has made an impressive comeback in 2025, with its stock soaring 45% so far this year. This sharp rebound follows a tough 2024, when its shares dropped over 40% due to missed earnings ...

CVS Health stock is way up but still offers a juicy ... The company also operates a leading pharmacy benefits management (PBM) business and Aetna, the medical-insurance giant.

There isn’t a widespread shortage of Oseltamivir, commonly known by its brand name Tamiflu. But you still might have issues ...